The size of the Antivenom Market in Europe is expected to reach USD 0.41 billion by 2024 from USD 0.3 billion in 2019, growing at a CAGR of 5.21% during the forecast period 2019 - 2024.
Antivenom is described as the biological product that detoxifies the poisoning of venomous bites. Antivenom is prepared from the milking venom of animals such as snakes, spiders, scorpions, and other venomous animals. Venomous bites result in certain clinical conditions such as secretion of excessive saliva, muscle weakness, breathing problems, and other difficulties that may lead to death also. It is estimated that approximately 15,000-20,000 people die with snake bites annually in Europe. To overcome poisonous effects after venomous bites the manufacturers developed a number of Antivenom products including vaccines and hyperimmune sera.
The growing involvement of research institutes to support the development of effective antivenom products, the existence of established medical care system, and the development of effective antivenom products against multiple venomous animals are driving the growth of Europe Antivenom Market.
However, stringent regulatory, high cost of the products, and limited accessibility of antivenom products are restraining the growth of Europe Antivenom Market.
This research report is segmented & sub-segmented the market into the following categories:
Noteworthy companies leading the Europe Antivenom Market are Instituto Bioclon, S.A. de C.V. (Mexico), Pfizer AG (Switzerland), CSL Limited (Australia), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (U.S.), Rare Disease Therapeutics, Inc. (U.S.), Vins Bioproducts Limited (India), BTG Plc (U.K.), Incepta Vaccine Ltd. (Bangladesh) and Bharat Serum.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 Vaccines
5.1.3 Hyperimmune Sera
5.1.3.1 Homologous
5.1.3.2 Heterologous
5.1.4 Y-o-Y Growth Analysis, By type
5.1.5 Market Attractiveness Analysis, By Type
5.1.6 Market Share Analysis, By Type
5.2 Animal
5.2.1 Introduction
5.2.2 Snakes
5.2.3 Scorpions
5.2.4 Spiders
5.2.5 Others
5.2.6 Y-o-Y Growth Analysis, By Animal
5.2.7 Market Attractiveness Analysis, By Animal
5.2.8 Market Share Analysis, By Animal
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.2 By Animal
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.2 By Animal
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.2 By Animal
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Instituto Bioclon, S.A. de C.V.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer AG
8.3 CSL Limited
8.4 Roche
8.5 Merck & Co
8.6 Rare Disease Therapeutics, Inc.
8.7 Vins Bioproducts Limited
8.8 BTG Plc
8.9 Incepta Vaccine Ltd
8.10 Bharat Serim and Vaccines Limited (BSV)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
